Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TCR2 Therapeutics Inc.    TCRR

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
26.72(c) 27.16(c) 26.35(c) 26.57(c) 27.75(c) Last
348 191 715 407 224 553 533 503 286 377 Volume
-3.99% +1.65% -2.98% +0.83% +4.44% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -67,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -11,3x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -86,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -10,8x
Yield 2021 -
Capitalization 926 M 926 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 109
Free-Float 85,3%
More Financials
Company
TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across... 
More about the company
Notations Surperformance© of TCR2 Therapeutics Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about TCR2 THERAPEUTICS INC.
11/12TCR2 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
11/12TCR2 THERAPEUTICS INC. : Results of Operations and Financial Condition, Financia..
AQ
11/12TCR2 THERAPEUTICS : TCR² Therapeutics Reports Third Quarter 2020 Financial Resul..
AQ
11/12TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides C..
GL
11/10TCR2 THERAPEUTICS : TCR² Therapeutics Announces Partnership with ElevateBio to E..
AQ
11/10TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manu..
GL
10/02TCR2 THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
09/30TCR2 THERAPEUTICS : TCR-2 Therapeutics to Present at Jefferies Cell Therapy Virt..
AQ
09/29TCR2 THERAPEUTICS : TCR² Therapeutics to Present at Jefferies Cell Therapy Virtu..
AQ
09/29TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
GL
09/08TCR2 Therapeutics to Participate in Two Upcoming Conferences in September
GL
09/08TCR2 THERAPEUTICS : to Participate in Two Upcoming Conferences in September
AQ
08/13TCR2 THERAPEUTICS : TCR-2 Therapeutics Reports Second Quarter 2020 Financial Res..
AQ
08/12TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides ..
GL
08/06TCR2 THERAPEUTICS : to Present at the Wedbush PacGrow Healthcare Conference
PU
More news
News in other languages on TCR2 THERAPEUTICS INC.

- No features available -

More news
Chart TCR2 THERAPEUTICS INC.
Duration : Period :
TCR2 Therapeutics Inc. Technical Analysis Chart | TCRR | US87808K1060 | MarketScreener
Technical analysis trends TCR2 THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 35,22 $
Last Close Price 27,75 $
Spread / Highest target 65,8%
Spread / Average Target 26,9%
Spread / Lowest Target 0,90%
EPS Revisions
Managers
NameTitle
Garry E. Menzel President, Chief Executive Officer & Director
Ansbert K. Gadicke Chairman
Amy V. Lynch Head-Operations & Human Resources
M. Ian Somaiya Chief Financial Officer
Robert Hofmeister Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TCR2 THERAPEUTICS INC.94.33%926
LONZA GROUP AG55.66%44 931
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 870
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832